Clinical Trial

Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Aim of the trial is to evaluate the activity and tolerability of the anti PD1 agent Pembrolizumab in combination with RadioTherapy for the initial treatment of previously untreated patients with limited stage NK/T cell lymphoma who are not eligible to chemotherapy. It is planned to enroll 30 patients in chinese sites. All eligible patients will be treated with standard radiotherapy and concurrent pembrolizumab administered intravenously every 3 weeks. After 6 cycles of pembrolizumab patients with complete remission, partial response and stable disease will continue with pembrolizumab maintenance up to 2 years. Patients will be followed up to 4 years from treatment start.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2020-06-02; most recent amendment 2026-04-01.
Status change: Recruiting → Active, Not Recruiting 2026-04-01
Status change: Not Yet Recruiting → Recruiting 2022-03-29
Trial Details
NCT Number NCT04417166
Lead Sponsor International Extranodal Lymphoma Study Group (IELSG)
Collaborators: Merck Sharp & Dohme LLC
Conditions Lymphoma, Extranodal NK-T-Cell
Enrollment 30 participants
Start Date 2022-02-11
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-07